Role of HCV Core gene of genotype 1a and 3a and host gene Cox-2 in HCV-induced pathogenesis

Virology Journal

Volumn 8, Issue , 2011, Pages

  Jahan, Shah ^a   Khaliq, Saba ^a   Ijaz, Bushra ^a   Ahmad, Waqar ^a   Hassan, Sajida ^a  

^a UNIVERSITY OF THE PUNJAB   (Pakistan)

Author keywords

[No Author keywords available]

Indexed keywords

CORE PROTEIN; CYCLOOXYGENASE 2; HEPATITIS C CORE ANTIGEN; INDUCIBLE NITRIC OXIDE SYNTHASE; PROSTAGLANDIN E2; PROTEIN KINASE B; SMALL INTERFERING RNA; UNCLASSIFIED DRUG; VASCULOTROPIN; VIRUS RNA; NUCLEOCAPSID PROTEIN, HEPATITIS C VIRUS; PTGS2 PROTEIN, HUMAN;

AMINO ACID SEQUENCE; ANGIOGENESIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; GENE OVEREXPRESSION; GENE SILENCING; GENOTYPE; HEPATITIS C VIRUS; NONHUMAN; NUCLEOTIDE SEQUENCE; OXIDATIVE STRESS; PLASMID; PROSTAGLANDIN RELEASE; VIRUS CELL INTERACTION; VIRUS GENE; VIRUS PATHOGENESIS; VIRUS REPLICATION; CHEMISTRY; CLASSIFICATION; DOWN REGULATION; GENE EXPRESSION REGULATION; GENETICS; HEPATITIS C; HUMAN; METABOLISM; MOLECULAR GENETICS; PATHOLOGY; PHYSIOLOGY; SEQUENCE ALIGNMENT; TUMOR CELL LINE; VIROLOGY;

HEPATITIS C VIRUS;

AMINO ACID SEQUENCE; CELL LINE, TUMOR; CYCLOOXYGENASE 2; DOWN-REGULATION; GENE EXPRESSION REGULATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; MOLECULAR SEQUENCE DATA; SEQUENCE ALIGNMENT; VIRAL CORE PROTEINS; VIRUS REPLICATION;

EID: 79953249749     PISSN: None     EISSN: 1743422X     Source Type: Journal    
DOI: 10.1186/1743-422X-8-155     Document Type: Article

References (52)

1. Hepatitis C virus biology. C Giannini C Brechot, Cell Death Differ 2003 10 27 S38 10.1038/sj.cdd.4401121 12655344
2. Epidemiology of hepatitis C virus infection in Pakistan. NS Raja KA Janjua, J Microbiol Immunol Infect 2008 41 4 8 18327420 (Pubitemid 351792115)
3. HCV genotype distribution and possible transmission risks in Lahore, Pakistan. W Ahmad B Ijaz FT Javed S Jahan I Shahid FM Khan,, et al. World J Gastroenterol 2010 16 4321 4328 10.3748/wjg.v16.i34.4321 20818816
4. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. M Okuda K Li MR Beard,, et al. Gastroenterology 2002 122 568 57/1 10.1053/gast.2002.30983 11832470
5. The core protein of hepatitis C virus induces hepatocellular carcinoma in transgenic mice. K Moriya H Fujie Y Shintani H Yotsuyanagi T Tsutsumi K Ishibashi,, et al. Nat Med 1998 4 1065 1067 10.1038/2053 9734402 (Pubitemid 28417341)
6. Hepatitis C virus, ER stress, and oxidative stress. KD Tardif G Waris A Siddiqui, Trends Microbiol 2005 13 159 163 10.1016/j.tim.2005.02.004 15817385 (Pubitemid 40463317)
7. Increased intrahepatic cyclooxygenase 2, matrix metalloproteinase 2, and matrix metalloproteinase 9 expression is associated with progressive liver disease in chronic hepatitis C virus infection: role of viral core and NS5A proteins. O Nunez A Fernandez-Martinez PL Majano A Apolinario M Gomez-Gonzalo I Benedicto,, et al. Gut 2004 53 1665 1672 10.1136/gut.2003.038364 15479690 (Pubitemid 39434113)
8. Expression of cyclooxygenase-2 in human hepatocellular carcinoma: relevance to tumor dedifferentiation. H Koga S Sakisaka M Ohishi T Kawaguchi E Taniguchi K Sasatomi,, et al. Hepatology 1999 29 688 696 10.1002/hep.510290355 10051469 (Pubitemid 29109581)
9. COX-2 - a target for preventing hepatic carcinoma? MA Rahman H Kohno N Nagasue, Expert Opin Ther Targets 2002 6 483 490 10.1517/14728222.6.4.483 12223062
10. Cox-2, iNOS and p53 as play-makers of tumor angiogenesis. V Chiarugi L Magnelli O Gallo, Int J Mol Med 1998 2 715 719 9850741
11. Cyclooxygenase-2 pathway correlates with vascular endothelial growth factor expression and tumor angiogenesis in hepatitis B virus-associated hepatocellular carcinoma. AS Cheng HL Chan KF To WK Leung KK Chan CT Liew,, et al. Int J Oncol 2004 24 853 860 15010822
12. Tumor cyclooxygenase-2 levels correlate with tumor invasiveness in human hepatocellular carcinoma. TC Tang RT Poon CP Lau D Xie ST Fan, World J Gastroenterol 2005 11 1896 1902 15800977 (Pubitemid 40520983)
13. Cyclooxygenase-2 promotes hepatocellular carcinoma cell growth through Akt activation: evidence for Akt inhibition in celecoxib-induced apoptosis. J Leng C Han AJ Demetris GK Michalopoulos T Wu, Hepatology 2003 38 756 768 10.1053/jhep.2003.50380 12939602 (Pubitemid 37052162)
14. AKT plays a central role in tumorigenesis. JR Testa A Bellacosa, Proc Natl Acad Sci USA 2001 98 10983 10985 10.1073/pnas.211430998 11572954 (Pubitemid 32928669)
15. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. I Vivanco CL Sawyers, Nat Rev Cancer 2002 2 489 501 10.1038/nrc839 12094235 (Pubitemid 37328931)
16. Interplay between oxidative stress and immunity in the progression of alcohol-mediated liver injury. M Vidali SF Stewart E Albano, Trends Mol Med 2008 14 63 71 10.1016/j.molmed.2007.12.005 18222109
17. Inhibition of Core gene of HCV 3a genotype using synthetic and vector derived siRNAs. S Khaliq S Jahan B Ijaz W Ahmad S Asad A Pervais,, et al. Virology J 2010 7 318 10.1186/1743-422X-7-318
18. Hepatitis C virus genotype 3a infection and hepatocellular carcinoma: Pakistan experience. M Idrees S Rafique I Rehman H Akbar MZ Yousaf S Butt,, et al. World J Gastroenterol 2009 15 5080 5085 10.3748/wjg.15.5080 19860002
19. Worldwide variation in the relative importance of hepatitis B and hepatitis C viruses in hepatocellular carcinoma: a systematic review. SA Raza GM Clifford S Franceschi, Br J Cancer 2007 96 1127 1134 10.1038/sj.bjc.6603649 17406349 (Pubitemid 46608308)
20. Impact of amino acid substitutions in the hepatitis C virus genotype 1b core region on liver steatosis and hepatic oxidative stress in patients with chronic hepatitis C. Y Tachi Y Katano T Honda K Hayashi M Ishigami A Itoh,, et al. Liver Int 2009 30 554 559 10.1111/j.1478-3231.2009.02164.x 19951380
21. Up-regulation of fatty acid synthase promoter by hepatitis C virus core protein: genotype-3a core has a stronger effect than genotype-1b core. C Jackel-Cram LA Babiuk Q Liu, J Hepatol 2007 46 999 1008 10.1016/j.jhep.2006.10. 019 17188392 (Pubitemid 46669729)
22. Potential involvement of the cyclooxygenase-2 pathway in hepatocellular carcinoma-associated angiogenesis. QT Zhao SQ Yue Z Cui Q Wang X Cui HH Zhai,, et al. Life Sci 2007 80 484 492 10.1016/j.lfs.2006.09.038 17097688 (Pubitemid 46019821)
23. Prostaglandins up-regulate vascular endothelial growth factor production through distinct pathways in differentiated U937 cells. H Bamba S Ota A Kato C Kawamoto K Fujiwara, Biochem Biophys Res Commun 2000 273 485 491 10.1006/bbrc.2000.2969 10873632 (Pubitemid 30599012)
24. Cyclooxygenase-2 pathway Correlates with VEGF expression in head and neck cancer. Implications for tumor angiogenesis and metastasis. O Gallo A Franhi L Magnelli I Sardi A Vannacci V Boddi,, et al. Neoplasia 2001 3 53 61 10.1038/sj.neo.7900127 11326316 (Pubitemid 32201610)
25. Characteristic mutations in hepatitis virus core gene related to the occurrence of hepatocellular carcinoma. Z Hu R Muroyama N Kowatari J Chang M Omata N Kato, Cancer Sci 2009 100 2465 2468 10.1111/j.1349-7006.2009.01338.x 20175782
26. Hepatitis C Virus core protein genotype 3a increases SOCS-7 expression through PPAR-{gamma} in Huh-7 cells. V Pazienza M Vinciguerra A Andriulli A Mangia, J Gen Virol 2010 91 1678 1686 10.1099/vir.0.020644-0 20357037
27. The genotype 3-specific hepatitis C virus core protein residue phenylalanine 164 increases steatosis in an in vitro cellular model. C Hourioux R Patient A Morin E Blanchard A Moreau S Trassard,, et al. Gut 2007 56 1302 1308 10.1136/gut.2006.108647 17213339 (Pubitemid 47300434)
28. Specific polymorphisms in hepatitis C virus genotype 3 core protein associated with intracellular lipid accumulation. R Jhaveri J McHutchison K Patel G Qiang AM Diehl, J Infect Dis 2008 197 283 291 10.1086/524846 18177246 (Pubitemid 351263449)
29. Prevalence of mutations in hepatitis C virus core protein associated with alteration of NF-kB activation. AE Mann S Stanford EK Sherman, Virus Research 2006 121 51 57 10.1016/j.virusres.2006.04.001 16723161 (Pubitemid 43994212)
30. Increased intrahepatic cyclooxygenase, matrix metalloproteinase, and matrix metalloproteinase expression is associated with progressive liver disease in chronic hepatitis C Virus infection: role of viral core and NS5A proteins. O Nunez A Fernandez-Martinez PL Majano A Apolinario M Gomez-Gonzalo I Benedicto M Lopez-Cabrera L Bosca G Clemente C Garcia-Monzon P Martin-Sanz, Gut 2004 53 1665 1672 10.1136/gut.2003.038364 15479690 (Pubitemid 39434113)
31. Amino acid substitutions in the hepatitis C virus core region of genotype 1b are the important predictor of severe insulin resistance in patients without cirrhosis and diabetes mellitus. N Akuta F Suzuki M Hirakawa Y Kawamura H Yatsuji H Sezaki,, et al. J Med Virol 2009 81 1032 1039 10.1002/jmv.21473 19382270
32. Association of amino acid substitution pattern in core protein of hepatitis C virus genotype 1b high viral load and non-virological response to interferon-ribavirin combination therapy. N Akuta F Suzuki H Sezaki Y Suzuki T Hosaka T Someya,, et al. Intervirology 2005 48 372 380 10.1159/000086064 16024941 (Pubitemid 41003622)
33. Pretreatment sequence diversity differences in the full-length hepatitis C virus open reading frame correlate with early response to therapy. MJ Donlin NA Cannon E Yao J Li A Wahed MW Taylor,, et al. J Virol 2007 81 8211 8224 10.1128/JVI.00487-07 17522222 (Pubitemid 47101507)
34. Inhibition of hepatitis C virus gene expression by small interfering RNAs using a tri-cistronic full-length viral replicon and a transient mouse model. M Kim D Shin SI Kim M Park, Virus Res 2006 122 1 10 10.1016/j.virusres.2006.05. 003 16979254 (Pubitemid 44634825)
35. RNA interference effectively inhibits mRNA accumulation and protein expression of hepatitis C virus core and E2 genes in human cells. M Liu H Ding P Zhao ZL Qin J Gao MM Cao,, et al. Biosci Biotechnol Biochem 2006 70 2049 2055 10.1271/bbb.60001 16960393 (Pubitemid 44451879)
36. Direct infection and replication of naturally occurring hepatitis C virus genotypes 1, 2, 3 and 4 in normal human hepatocyte cultures. M Buck, PLoS One 2008 3 2660 10.1371/journal.pone.0002660 18628977
37. HepG2 cells support viral replication and gene expression of hepatitis C virus genotype 4 in vitro. MK el-Awady AA Tabll YS el-Abd MM Bahgat HA Shoeb SS Youssef,, et al. World J Gastroenterol 2006 12 4836 4842 16937465 (Pubitemid 44323208)
38. Hepatitis C virus replication in transfected and serum-infected cultured human fetal hepatocytes. CA Lazaro M Chang W Tang J Campbell DG Sullivan DR Gretch,, et al. Am J Pathol 2007 170 478 489 10.2353/ajpath.2007.060789 17255316 (Pubitemid 47339385)
39. Serum-derived hepatitis C virus infection of primary human hepatocytes is tetraspanin CD81 dependent. S Molina V Castet L Pichard-Garcia C Wychowski E Meurs JM Pascussi,, et al. J Virol 2008 82 569 574 10.1128/JVI.01443-07 17942559 (Pubitemid 350309172)
40. Consensus siRNA for inhibition of HCV genotype-4 replication. AR Zekri AA Bahnassy HM El-Din HM Salama, Virol J 2009 6 13 10.1186/1743-422X-6-13 19173711
41. Inhibition of HCV 3a genotype by siRNAs targeting envelope genes. S Khaliq S Jahan B Ijaz W Ahmad S Asad S Hassan, Arch Virol 2010 156 3 433 442 10.1007/s00705-010-0887-6 21161551
42. Simultaneous targeting of HCV replication and viral binding with a single lentiviral vector containing multiple RNA interference expression cassettes. SD Henry WP van der HJ Metselaar HW Tilanus BJ Scholte LJ van der Laan, Mol Ther 2006 14 485 493 10.1016/j.ymthe.2006.04.012 16872906 (Pubitemid 44296093)
43. Inhibition of hepatitis C virus translation and subgenomic replication by siRNAs directed against highly conserved HCV sequence and cellular HCV cofactors. M Korf D Jarczak C Beger MP Manns M Kruger, J Hepatol 2005 43 225 234 10.1016/j.jhep.2005.02.046 15964661 (Pubitemid 40956874)
44. Hsp90 inhibitors suppress HCV replication in replicon cells and humanized liver mice. S Nakagawa T Umehara C Matsuda S Kuge M Sudoh M Kohara, Biochem Biophys Res Commun 2007 353 882 888 10.1016/j.bbrc.2006.12.117 17196931 (Pubitemid 46080379)
45. Clearance of replicating hepatitis C virus replicon RNAs in cell culture by small interfering RNAs. G Randall A Grakoui CM Rice, Proc Natl Acad Sci USA 2003 100 235 240 10.1073/pnas.0235524100 12518066 (Pubitemid 36078058)
46. RNA interference targeting Fas protects mice from fulminant hepatitis. E Song SK Lee J Wang N Ince N Ouyang J Min,, et al. Nat Med 2003 9 347 351 10.1038/nm828 12579197 (Pubitemid 36362792)
47. Caspase 8 small interfering RNA prevents acute liver failure in mice. L Zender S Hutker C Liedtke HL Tillmann S Zender B Mundt,, et al. Proc Natl Acad Sci USA 2003 100 7797 7802 10.1073/pnas.1330920100 12810955 (Pubitemid 36760049)
48. A transgenic mouse model of steatosis and hepatocellular carcinoma associated with chronic hepatitis C virus infection in humans. SM Lemon H Lerat SA Weinman M Honda, Trans Am Clin Climatol Assoc 2000 111 146 156 10881339
49. Steatosis and liver cancer in transgenic mice expressing the structural and nonstructural proteins of hepatitis C virus. H Lerat M Honda MR Beard,, et al. Gastroenterology 2002 122 352 365 10.1053/gast.2002.31001 11832450 (Pubitemid 34116987)
50. Hepatic steatosis is a risk factor for hepatocellular carcinoma in patients with chronic hepatitis C virus infection. K Ohata K Hamasaki K Toriyama,, et al. Cancer 2003 97 3036 3043 10.1002/cncr.11427 12784339 (Pubitemid 36676258)
51. Hepatitis C virus core protein induces hepatic steatosis in transgenic mice. K Moriya H Yotsuyanagi Y Shintani H Fujie K Ishibashi Y Matsuura T Miyamura K Koike, J Gen Virol 1997 78 1527 1531 9225025 (Pubitemid 27343089)
52. Repeated hepatocyte injury promotes hepatic tumorigenesis in hepatitis C virus transgenic mice. T Kato M Miyamoto T Date,, et al. Cancer Sci 2003 94 679 68 10.1111/j.1349-7006.2003.tb01502.x 12901792